A systematic review investigating the proportion of clinical images shared in prospective randomized controlled trials involving patients with atopic dermatitis and systemic pharmacotherapy

Figures & data

Figure 1. PRISMA flow chart. PRISMA: Preferred Reporting Items for Systematic Reviews and Meta-Analyses.

Table 1. List of investigations (n = 4) with included patient images in running manuscripts and supplements.

First author	Year	Journal	Primary outcome	Time to primary outcome	Number of randomized patients	Number of patients depicted in manuscript^a	Number of patient images in manuscript^a	Proportion of depicted patients^a	Digital Object Identifier link
Bemanian et al. (26)	2005	Iran J Allergy Asthma Immunol	SCORAD	N/A	14	1	2	7.1%	N/A
Gooderham et al. (37)^b	2019	JAMA Dermatol	IGA	12 weeks	267	3	9	1.1%	https://doi.org/10.1001/jamadermatol.2019.2855
Gutermuth et al. (40)	2022	Br J Dermatol	ΔEASI 75	16 weeks	277	1	2	0.4%	https://doi.org/10.1111/bjd.20832
Wollenberg et al. (79)	2021	Br J Dermatol	ΔEASI 75 + IGA	16 weeks	1596	1	3	0.6‰	https://doi.org/10.1111/bjd.19574

Notes: Journal abbreviations: Br J Derm: British Journal of Dermatology; Iran J Allergy Asthma Immunol: Iranian Journal of Allergy, Asthma and Immunology; JAMA Dermatol: Journal of the American Medical Association Dermatology. Primary outcome abbreviations: EASI: Eczema Area and Severity Index; EASI 75: 75% improvement of the EASI value as compared to baseline; IGA: Investigators Global Assessment; NA: not available or not available.

^a Running manuscript and all supplementary material combined.

^bImage material were made available in supplementary material.

Table 2. Proportion of depicted patients in the five journals with most randomized patients.

Journal	Number of investigations	Number of randomized patients	Number of patients depicted in running manuscript	Number of patient images in running manuscript	Number of patients depicted in supplements^a	Number of patient images in supplements^a	Proportion of depicted patients^b
Br J Dermatol	19	5657	2	5	0	0	0.4‰
Lancet	9	5076	0	0	0	0	0%
JAMA Derm	7	2516	0	0	3	9	0.10%
N Engl J Med	3	2424	0	0	0	0	0%
J Am Acad Dermatol	5	1092	0	0	0	0	0%
	43	16,765	2	5	3	9	0.3‰

Note: Br J Dermatol: British Journal of Dermatology; J Am Acad Dermatol: Journal of the American Academy of Dermatology; JAMA Dermatology: Journal of the American Medical Association Dermatology; N Engl J Med, New England Journal of Medicine.

^a Including video supplements.

^bIncluding both running manuscript and any supplementary material.

Bemanian MH, Movahedi M, Farhoudi A, et al. High doses intravenous immunoglobulin versus oral cyclosporine in the treatment of severe atopic dermatitis. Iran J Allergy Asthma Immunol. 2005;4:139–143.

 PubMedGoogle Scholar

Gooderham MJ, Forman SB, Bissonnette R, et al. Efficacy and safety of oral janus kinase 1 inhibitor abrocitinib for patients with atopic dermatitis: a phase 2 randomized clinical trial. JAMA Dermatol. 2019;155(12):1371–1379. doi: 10.1001/jamadermatol.2019.2855.

 PubMed Web of Science ®Google Scholar

Gutermuth J, Pink AE, Worm M, et al. Tralokinumab plus topical corticosteroids in adults with severe atopic dermatitis and inadequate response to or intolerance of ciclosporin A: a placebo-controlled, randomized, phase III clinical trial (ECZTRA 7). Br J Dermatol. 2022;186(3):440–452. doi: 10.1111/bjd.20832.

 PubMed Web of Science ®Google Scholar

Wollenberg A, Blauvelt A, Guttman-Yassky E, et al. Tralokinumab for moderate-to-severe atopic dermatitis: results from two 52-week, randomized, double-blind, multicentre, placebo-controlled phase III trials (ECZTRA 1 and ECZTRA 2). Br J Dermatol. 2021;184(3):437–449. doi: 10.1111/bjd.19574.

 PubMed Web of Science ®Google Scholar